BioSpace Global Roundup: Cevec Licenses AAV Program to Biogen
The Pharma Data
JANUARY 13, 2021
Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. Few details of the deal were disclosed in the announcement. provided an update on its ongoing NASH program.
Let's personalize your content